Literature DB >> 30121940

Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.

Daniel Lubin1, Ezra Baraban2, Amanda Lisby2, Sahar Jalali-Farahani2, Paul Zhang2, Virginia Livolsi2.   

Abstract

There is evidence that programmed death-ligand 1 (PD-L1) is expressed by thyroid follicular epithelium in thyroiditis, but the role of PD-L1 in papillary thyroid carcinoma (PTC) is poorly understood. We aimed to determine whether (1) the presence of background chronic lymphocytic thyroiditis (CLT) or Hashimoto thyroiditis (HT) influenced the expression of PD-L1 in benign follicular epithelium or in PTC and (2) if PD-L1 expression in PTC persisted with lymph node metastasis. We performed immunohistochemistry (IHC) for PD-L1 on formalin-fixed paraffin-embedded tissues. We first studied five cases of unremarkable thyroid, five cases of CLT, and five cases of HT without carcinoma. We subsequently performed PD-L1 IHC on ten cases of PTC arising in normal thyroid, ten cases of PTC arising in CLT, and ten cases of PTC arising in HT. Whenever available, we evaluated corresponding synchronous lymph node metastases from all cases for PD-L1 expression. PD-L1 expression was increased (10-90%) in all five cases of HT, only minimal expressed (1-5%) in two of five cases of CLT, and not expressed in five cases of unremarkable thyroid. PTC arising in normal thyroid or CLT nearly uniformly lacked PD-L1 expression. In contrast, PTC arising in HT demonstrated significant PD-L1 expression, which persisted in corresponding lymph node metastases. Background non-neoplastic follicular epithelium in the HT cases also demonstrated PD-L1 expression. Thyroid follicular epithelium in HT demonstrates increased PD-L1 expression, and PTC arising in a background of HT shows increased PD-L1 expression, which is retained with metastasis.

Entities:  

Keywords:  Hashimoto thyroiditis; Metastasis; Papillary thyroid carcinoma; Programmed death-ligand 1; Thyroid

Mesh:

Substances:

Year:  2018        PMID: 30121940     DOI: 10.1007/s12022-018-9540-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  22 in total

1.  Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome.

Authors:  B Singh; A R Shaha; H Trivedi; J F Carew; A Poluri; J P Shah
Journal:  Surgery       Date:  1999-12       Impact factor: 3.982

Review 2.  Pembrolizumab (Keytruda).

Authors:  Gerry Kwok; Thomas C C Yau; Joanne W Chiu; Eric Tse; Yok-Lam Kwong
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

3.  Papillary-cystic pattern is characteristic in mammary analogue secretory carcinomas but is rarely observed in acinic cell carcinomas of the salivary gland.

Authors:  Min-Shu Hsieh; Yueh-Hung Chou; Shin-Joe Yeh; Yih-Leong Chang
Journal:  Virchows Arch       Date:  2015-05-15       Impact factor: 4.064

4.  Comprehensive screening for PD-L1 expression in thyroid cancer.

Authors:  Soomin Ahn; Tae Hyuk Kim; Sun Wook Kim; Chang Seok Ki; Hye Won Jang; Jee Soo Kim; Jung Han Kim; Jun-Ho Choe; Jung Hee Shin; Soo Yeon Hahn; Young Lyun Oh; Jae Hoon Chung
Journal:  Endocr Relat Cancer       Date:  2017-02       Impact factor: 5.678

5.  Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.

Authors:  Koichi Sato; Hiroaki Akamatsu; Eriko Murakami; Seigo Sasaki; Kuninobu Kanai; Atsushi Hayata; Nahomi Tokudome; Keiichiro Akamatsu; Yasuhiro Koh; Hiroki Ueda; Masanori Nakanishi; Nobuyuki Yamamoto
Journal:  Lung Cancer       Date:  2017-11-21       Impact factor: 5.705

6.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.

Authors:  Hyeyeun Lim; Susan S Devesa; Julie A Sosa; David Check; Cari M Kitahara
Journal:  JAMA       Date:  2017-04-04       Impact factor: 56.272

7.  Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Authors:  Ian D Hay; Geoffrey B Thompson; Clive S Grant; Eric J Bergstralh; Catherine E Dvorak; Colum A Gorman; Megan S Maurer; Bryan McIver; Brian P Mullan; Ann L Oberg; Claudia C Powell; Jon A van Heerden; John R Goellner
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

8.  PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Authors:  Matthew W Rosenbaum; Benjamin J Gigliotti; Sara I Pai; Sareh Parangi; Heather Wachtel; Mari Mino-Kenudson; Viswanath Gunda; William C Faquin
Journal:  Endocr Pathol       Date:  2018-03       Impact factor: 3.943

9.  Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.

Authors:  Subrata Chowdhury; Joe Veyhl; Fatima Jessa; Olena Polyakova; Ahmed Alenzi; Christina MacMillan; Ranju Ralhan; Paul G Walfish
Journal:  Oncotarget       Date:  2016-05-31

10.  Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.

Authors:  Edwin R Parra; Pamela Villalobos; Barbara Mino; Jaime Rodriguez-Canales
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-02
View more
  10 in total

1.  Hashimoto's Thyroiditis Is Associated With Central Lymph Node Metastasis in Classical Papillary Thyroid Cancer: Analysis from a High-Volume Single-Center Experience.

Authors:  Bin Zeng; Yu Min; Yang Feng; Ke Xiang; Hang Chen; Zijing Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-20       Impact factor: 6.055

2.  Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.

Authors:  Anupam Kotwal; Michael P Gustafson; Svetlana Bornschlegl; Lisa Kottschade; Danae A Delivanis; Allan B Dietz; Manish Gandhi; Mabel Ryder
Journal:  Thyroid       Date:  2020-05-21       Impact factor: 6.506

Review 3.  From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer.

Authors:  Grégoire D'Andréa; Sandra Lassalle; Nicolas Guevara; Baharia Mograbi; Paul Hofman
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

4.  T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.

Authors:  Chumeng Zhu; Yuechu Dai; Hui Zhang; Yanyun Ruan; Yong Zhou; Yingjie Dai; Lilong Fan; Tianjun Jia; Hongsheng Lu; Qi Chen
Journal:  Diagn Pathol       Date:  2021-08-31       Impact factor: 2.644

5.  Analysis of anti-apoptotic PVT1 oncogene and apoptosis-related proteins (p53, Bcl2, PD-1, and PD-L1) expression in thyroid carcinoma.

Authors:  Afaf T Ibrahiem; Amin K Makhdoom; Khalid S Alanazi; Abdulaziz M Alanazi; Abdulaziz M Mukhlef; Saad H Elshafey; Eman A Toraih; Manal S Fawzy
Journal:  J Clin Lab Anal       Date:  2022-04-07       Impact factor: 3.124

6.  PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor.

Authors:  Emma Pakkanen; David Kalfert; Maarit Ahtiainen; Marie Ludvíková; Teijo Kuopio; Ivana Kholová
Journal:  APMIS       Date:  2022-03-13       Impact factor: 3.428

Review 7.  Thyroid-related adverse events induced by immune checkpoint inhibitors.

Authors:  Alexandra Chera; Andreea Lucia Stancu; Octavian Bucur
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-20       Impact factor: 6.055

8.  Peripheral Versus Intraparenchymal Papillary Thyroid Microcarcinoma: Different Morphologies and PD-L1 Expression.

Authors:  Bozidar Kovacevic; Dragana Vucevic; Snezana Cerovic; Catarina Eloy
Journal:  Head Neck Pathol       Date:  2021-06-02

Review 9.  The exploration of Hashimoto's Thyroiditis related miscarriage for better treatment modalities.

Authors:  Yu Min; Xing Wang; Hang Chen; Guobing Yin
Journal:  Int J Med Sci       Date:  2020-08-29       Impact factor: 3.738

10.  CKS1B promotes cell proliferation and invasion by activating STAT3/PD-L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma.

Authors:  Hui Wang; Zhengdong Zhang; Zhe Yan; Shihong Ma
Journal:  J Clin Lab Anal       Date:  2020-09-22       Impact factor: 2.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.